CNBC's Jim Cramer reports on the latest news regarding Moderna.

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

Moderna shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

Moderna (MRNA) stock has fallen 71% over the last six months. While there’s still potential for near-term revenue tailwinds ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.

Analyst Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report) and decreased the price target to $50.00 from $55.00. Don't Miss our Black Friday Offers: Unlock your ...

Shares in biotech firm Moderna (NASDAQ: MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Shares of Moderna Inc (BMV: MRNA) (NASDAQ: MRNA) were up roughly 7% at $41, while those of Pfizer Inc (NYSE: PFE )were up ...